This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis.
This study is a 69 week open label study of autologous bone-marrow-derived mesenchymal stem cells (STR04) in participants with ALS. Participants will undergo a screening visit, followed by collection of peripheral blood and bone marrow for the manufacture of STR04. Once manufacturing is successfully completed, participants will have a Baseline visit followed by 4 doses of STR04, one dose every 12 weeks. Participants will have a final assessments 12 weeks after the 4th dose.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1
autologous bone-marrow-derived mesenchymal stem cells
National Neuromuscular Research Institute
Austin, Texas, United States
Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Score
Time frame: 25 weeks
Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Score
Time frame: 49 weeks
Change in Percent-predicted forced vital capacity (%FVC)
Time frame: From Baseline to 25 weeks and 49 weeks
Change in Manual Muscle Test (MMT)
Time frame: From Baseline to 25 weeks and 49 weeks
Change in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)
Time frame: From Baseline to 25 weeks and 49 weeks
Change in plasma neurofilament light (NfL)
Time frame: From Baseline to 25 weeks and 49 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.